↓ Skip to main content

Adenosine Receptors in Health and Disease

Overview of attention for book
Cover of 'Adenosine Receptors in Health and Disease'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Introduction to Adenosine Receptors as Therapeutic Targets
  3. Altmetric Badge
    Chapter 2 A 1 Adenosine Receptor Antagonists, Agonists, and Allosteric Enhancers
  4. Altmetric Badge
    Chapter 3 Recent Developments in Adenosine A 2A Receptor Ligands
  5. Altmetric Badge
    Chapter 4 Recent Developments in A 2B Adenosine Receptor Ligands
  6. Altmetric Badge
    Chapter 5 Medicinal Chemistry of the A 3 Adenosine Receptor: Agonists, Antagonists, and Receptor Engineering
  7. Altmetric Badge
    Chapter 6 Adenosine Receptors and the Heart: Role in Regulation of Coronary Blood Flow and Cardiac Electrophysiology
  8. Altmetric Badge
    Chapter 7 Adenosine Receptors in Health and Disease
  9. Altmetric Badge
    Chapter 8 Adenosine Receptors and Inflammation
  10. Altmetric Badge
    Chapter 9 A 1 Adenosine Receptor: Role in Diabetes and Obesity
  11. Altmetric Badge
    Chapter 10 A 3 Adenosine Receptor: Pharmacology and Role in Disease
  12. Altmetric Badge
    Chapter 11 Adenosine Receptors and Asthma
  13. Altmetric Badge
    Chapter 12 Adenosine Receptors, Cystic Fibrosis, and Airway Hydration
  14. Altmetric Badge
    Chapter 13 Adenosine Receptors in Wound Healing, Fibrosis and Angiogenesis
  15. Altmetric Badge
    Chapter 14 Adenosine receptors and cancer.
  16. Altmetric Badge
    Chapter 15 Adenosine Receptors in Health and Disease
  17. Altmetric Badge
    Chapter 16 Adenosine Receptors and the Central Nervous System
  18. Altmetric Badge
    Chapter 17 Adenosine Receptors and Neurological Disease: Neuroprotection and Neurodegeneration
  19. Altmetric Badge
    Chapter 18 Adenosine A 2A Receptors and Parkinson’s Disease
  20. Altmetric Badge
    Chapter 19 Adenosine Receptor Ligands and PET Imaging of the CNS
Attention for Chapter 16: Adenosine Receptors and the Central Nervous System
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news
1 news outlet
facebook
1 Facebook page

Citations

dimensions_citation
86 Dimensions

Readers on

mendeley
226 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Adenosine Receptors and the Central Nervous System
Chapter number 16
Book title
Adenosine Receptors in Health and Disease
Published in
Handbook of experimental pharmacology, February 2016
DOI 10.1007/978-3-540-89615-9_16
Pubmed ID
Book ISBNs
978-3-54-089614-2, 978-3-54-089615-9
Authors

Ana M. Sebastião, Joaquim A. Ribeiro, Sebastião, Ana M., Ribeiro, Joaquim A.

Abstract

The adenosine receptors (ARs) in the nervous system act as a kind of "go-between" to regulate the release of neurotransmitters (this includes all known neurotransmitters) and the action of neuromodulators (e.g., neuropeptides, neurotrophic factors). Receptor-receptor interactions and AR-transporter interplay occur as part of the adenosine's attempt to control synaptic transmission. A(2A)ARs are more abundant in the striatum and A(1)ARs in the hippocampus, but both receptors interfere with the efficiency and plasticity-regulated synaptic transmission in most brain areas. The omnipresence of adenosine and A(2A) and A(1) ARs in all nervous system cells (neurons and glia), together with the intensive release of adenosine following insults, makes adenosine a kind of "maestro" of the tripartite synapse in the homeostatic coordination of the brain function. Under physiological conditions, both A(2A) and A(1) ARs play an important role in sleep and arousal, cognition, memory and learning, whereas under pathological conditions (e.g., Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, stroke, epilepsy, drug addiction, pain, schizophrenia, depression), ARs operate a time/circumstance window where in some circumstances A(1)AR agonists may predominate as early neuroprotectors, and in other circumstances A(2A)AR antagonists may alter the outcomes of some of the pathological deficiencies. In some circumstances, and depending on the therapeutic window, the use of A(2A)AR agonists may be initially beneficial; however, at later time points, the use of A(2A)AR antagonists proved beneficial in several pathologies. Since selective ligands for A(1) and A(2A) ARs are now entering clinical trials, the time has come to determine the role of these receptors in neurological and psychiatric diseases and identify therapies that will alter the outcomes of these diseases, therefore providing a hopeful future for the patients who suffer from these diseases.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 226 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 <1%
Argentina 2 <1%
Portugal 1 <1%
Canada 1 <1%
Unknown 220 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 33 15%
Student > Master 31 14%
Researcher 29 13%
Student > Ph. D. Student 24 11%
Student > Doctoral Student 10 4%
Other 47 21%
Unknown 52 23%
Readers by discipline Count As %
Medicine and Dentistry 46 20%
Neuroscience 41 18%
Agricultural and Biological Sciences 29 13%
Psychology 14 6%
Pharmacology, Toxicology and Pharmaceutical Science 7 3%
Other 28 12%
Unknown 61 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 October 2017.
All research outputs
#2,872,433
of 22,774,233 outputs
Outputs from Handbook of experimental pharmacology
#99
of 646 outputs
Outputs of similar age
#54,428
of 400,584 outputs
Outputs of similar age from Handbook of experimental pharmacology
#8
of 50 outputs
Altmetric has tracked 22,774,233 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 646 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,584 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.